Literature DB >> 12761348

Aryl hydrocarbon receptor gene silencing with small inhibitory RNA differentially modulates Ah-responsiveness in MCF-7 and HepG2 cancer cells.

Maen Abdelrahim1, Roger Smith, Stephen Safe.   

Abstract

Sequence-specific small interfering RNA (siRNA) duplexes can be used for gene silencing in mammalian cells and as mechanistic probes for determining gene function. Transfection of siRNAs for the aryl hydrocarbon receptor (AhR) and AhR nuclear translocator (ARNT) mRNAs in MCF-7 breast cancer cells resulted in a 60 to 80% decrease in levels of AhR and ARNT proteins in whole-cell extracts and decreased binding of nuclear extracts to 32P-labeled dioxin-responsive element. siRNA for the AhR also decreased 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced CYP1A1 protein, CYP1A1-dependent activity, and luciferase activity in cells transfected with an Ah-responsive construct. 17beta-estradiol (E2) induces proliferation of MCF-7 cells through enhanced G0/G1 --> S phase progression, and this response is inhibited in cells cotreated with E2 plus TCDD. The effects of TCDD on E2-induced cell-cycle progress were partially blocked in MCF-7 cells transfected with siRNA for AhR. The results also indicated that siRNA-dependent decreases in AhR protein in MCF-7 cells were accompanied by increased G0/G1 --> S phase progression, suggesting a growth-inhibitory role for the "endogenous" AhR. Surprisingly, TCDD alone induced G0/G1 --> S phase progression and exhibited estrogenic activity in MCF-7 cells transfected with siRNA for the AhR. In contrast, degradation of the AhR in HepG2 liver cancer cells resulted in decreased G0/G1 --> S phase progression, and this was accompanied by decreased expression of cyclin D1, cyclin E, cyclin-dependent kinase 2 (cdk2), and cdk4. In the absence of ligand, the AhR exhibits growth-inhibitory (MCF-7) and growth-promoting (HepG2) activity that is cell context-dependent.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12761348     DOI: 10.1124/mol.63.6.1373

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  44 in total

1.  Expression of the aryl hydrocarbon receptor is not required for the proliferation, migration, invasion, or estrogen-dependent tumorigenesis of MCF-7 breast cancer cells.

Authors:  Barbara C Spink; James A Bennett; Nicole Lostritto; Jacquelyn R Cole; David C Spink
Journal:  Mol Carcinog       Date:  2012-03-02       Impact factor: 4.784

2.  The aryl hydrocarbon receptor contributes to the proliferation of human medulloblastoma cells.

Authors:  Daniel P Dever; Lisa A Opanashuk
Journal:  Mol Pharmacol       Date:  2012-02-06       Impact factor: 4.436

3.  Targeting of aryl hydrocarbon receptor-mediated activation of cyclooxygenase-2 expression by the indole-3-carbinol metabolite 3,3'-diindolylmethane in breast cancer cells.

Authors:  Stephanie C Degner; Andreas J Papoutsis; Ornella Selmin; Donato F Romagnolo
Journal:  J Nutr       Date:  2008-12-03       Impact factor: 4.798

Review 4.  Regulation of constitutive and inducible AHR signaling: complex interactions involving the AHR repressor.

Authors:  Mark E Hahn; Lenka L Allan; David H Sherr
Journal:  Biochem Pharmacol       Date:  2008-09-20       Impact factor: 5.858

Review 5.  The evolving role of the aryl hydrocarbon receptor (AHR) in the normophysiology of hematopoiesis.

Authors:  Stephan Lindsey; Eleftherios T Papoutsakis
Journal:  Stem Cell Rev Rep       Date:  2012-12       Impact factor: 5.739

Review 6.  Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action.

Authors:  Erin K Shanle; Wei Xu
Journal:  Chem Res Toxicol       Date:  2010-11-05       Impact factor: 3.739

7.  Malignant transformation of mammary epithelial cells by ectopic overexpression of the aryl hydrocarbon receptor.

Authors:  J Brooks; S E Eltom
Journal:  Curr Cancer Drug Targets       Date:  2011-06       Impact factor: 3.428

8.  Ah receptor-mediated suppression of liver regeneration through NC-XRE-driven p21Cip1 expression.

Authors:  Daniel P Jackson; Hui Li; Kristen A Mitchell; Aditya D Joshi; Cornelis J Elferink
Journal:  Mol Pharmacol       Date:  2014-01-15       Impact factor: 4.436

9.  The aryl hydrocarbon receptor as a target for estrogen receptor-negative breast cancer chemotherapy.

Authors:  Shu Zhang; Ping Lei; Xinyi Liu; Xiangrong Li; Kelcey Walker; Leela Kotha; Craig Rowlands; Stephen Safe
Journal:  Endocr Relat Cancer       Date:  2009-05-15       Impact factor: 5.678

10.  A novel role of the aryl hydrocarbon receptor (AhR) in centrosome amplification - implications for chemoprevention.

Authors:  Nina Korzeniewski; Sarah Wheeler; Payel Chatterjee; Anette Duensing; Stefan Duensing
Journal:  Mol Cancer       Date:  2010-06-17       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.